Cephalon Receives Approvable Letter for Fentora (Fentanyl Buccal Tablet) for Management of Breakthrough Pain in Patients with Cancer.
Cephalon Inc. announced that it has received an approvable letter from the U.S. Food and Drug Administration for FENTORA (fentanyl buccal tablet) [C-II]. The company submitted a new drug application in August 2005, seeking to market FENTORA for the treatment of breakthrough pain in opioid-tolerant patients with cancer.
